

Title (en)
ANTI-SARS-COV-2 ANTIBODIES

Title (de)
ANTI-SARS-COV-2-ANTIKÖRPER

Title (fr)
ANTICORPS ANTI-SRAS-COV-2

Publication
EP 4349860 A1 20240410 (EN)

Application
EP 22382940 A 20221006

Priority
EP 22382940 A 20221006

Abstract (en)
The present invention refers to antibodies or antigen-binding fragments thereof that bind the SARS-CoV-2 spike protein with high affinity and subsequent high neutralizing activity against SARS-CoV-2. It also discloses polynucleotides and expression vectors encoding said antibodies or antigen-binding fragments, and host cells comprising said nucleotides and vectors, as well as their use in treatment or prevention of a disease caused by a SARS-CoV-2.

IPC 8 full level
C07K 16/10 (2006.01); **A61P 31/14** (2006.01)

CPC (source: EP)
A61P 31/14 (2018.01); **C07K 16/1003** (2023.08); **C07K 2317/21** (2013.01); **C07K 2317/34** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/92** (2013.01)

Citation (applicant)

- US 10787501 B1 20200929 - BABB ROBERT [US], et al
- TONGQING ZHOU ET AL.: "Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B. 1.1.529", SCIENCE, vol. 376, 2022
- BRUEL, T. ET AL.: "Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies", NAT MED, 2022, Retrieved from the Internet <URL:https://doi.org/10.1038/s41591-022-01792-5>
- NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
- RICE ET AL.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS GENET., vol. 16, 2000, pages 276 - 277, XP004200114, DOI: 10.1016/S0168-9525(00)02024-2
- ALTSCHUL ET AL.: "Basic local alignment search tool", J. MOL. BIOL., vol. 215, 1990, pages 403 - 410, XP002949123, Retrieved from the Internet <URL:https://doi.org/10.1016/S0022-2836(05)80360-2> DOI: 10.1006/jmbi.1990.9999
- WARDEMAN HBUSSE CE: "Expression Cloning of Antibodies from Single Human B Cells", METHODS MOL BIOL., vol. 1956, 2019, pages 105 - 125
- PRADENAS E ET AL.: "Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals", FRONT. IMMUNOL., vol. 13, 2022, pages 860215
- RUTH I. CONNOR ET AL.: "Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1", MONONUCLEAR PHAGOCYTES, VIROLOGY, vol. 206, 1995, pages 935 - 944, XP002443025, DOI: 10.1006/viro.1995.1016
- TRINITE, B. ET AL.: "SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity", SCI REP, vol. 11, 2021, pages 2608, Retrieved from the Internet <URL:https://doi.org/10.1038/s41598-021-81862-9>
- PINTO, D. ET AL.: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody", NATURE, vol. 583, 2020, pages 290 - 295, XP037289888, Retrieved from the Internet <URL:https://doi.org/10.1038/s41586-020-2349-y> DOI: 10.1038/s41586-020-2349-y
- TORTORICI ET AL.: "Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms", SCIENCE, vol. 370, 2020, pages 6519
- TARRES-FREIXAS ET AL.: "Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice", FRONTIERS IN MICROBIOLOGY, vol. 13, 2022
- BRUSTOLIN ET AL.: "Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster", EMERGING MICROBES & INFECTIONS, vol. 10, no. 1, 2021, pages 797 - 809
- VIDAL ET AL.: "Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice", VET PATHOL., vol. 59, no. 4, July 2022 (2022-07-01), pages 613 - 626
- VIDAL ET AL.: "Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice", VET PATHOL., vol. 59, no. 4, July 2022 (2022-07-01), pages 613 - 626
- TONGQING ZHOU ET AL.: "Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529", SCIENCE, vol. 376, 2022, Retrieved from the Internet <URL:https://doi.org/10.1126/science.abn8897>
- BRUEL, T. ET AL.: "Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1.BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies", NAT MED, 2022, Retrieved from the Internet <URL:https://doi.org/10.1038/s41591-022-01792-5>
- RUTH I. CONNOR ET AL.: "Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes", VIROLOGY, vol. 206, 1995, pages 935 - 944, XP002443025, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0042682285710161> DOI: 10.1006/viro.1995.1016

Citation (search report)

- [IY] CN 114044821 A 20220215 - INST MILITARY MEDICINE ACADEMY MILITARY SCIENCES PLA
- [IY] ZHOU BIAO ET AL.: "A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge", NATURE COMMUNICATIONS, vol. 13, no. 1, 23 June 2022 (2022-06-23), XP093028307, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-022-31259-7.pdf> DOI: 10.1038/s41467-022-31259-7
- [IY] FENWICK CRAIG ET AL.: "Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys", NATURE MICROBIOLOGY, vol. 7, no. 9, 25 July 2022 (2022-07-25), pages 1376 - 1389, XP093027875, Retrieved from the Internet <URL:https://www.nature.com/articles/s41564-022-01198-6.pdf> DOI: 10.1038/s41564-022-01198-6
- [Y] NEWMAN JOSEPH ET AL.: "Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2", NATURE MICROBIOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 7, no. 8, 14 July 2022 (2022-07-14), pages 1180 - 1188, XP037925795, DOI: 10.1038/s41564-022-01163-3
- [Y] CAMERONI ELISABETTA ET AL.: "Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 602, no. 7898, 23 December 2021 (2021-12-23), pages 664 - 670, XP037700797, ISSN: 0028-0836, [retrieved on 20211223], DOI: 10.1038/s41586-021-04386-2

- [IY] PLANCHAIS CYRIL ET AL: "Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 219, no. 7, 15 June 2022 (2022-06-15), US, XP055934256, ISSN: 0022-1007, Retrieved from the Internet <URL:https://rupress.org/jem/article-pdf/doi/10.1084/jem.20220638/1434941/jem_20220638.pdf> DOI: 10.1084/jem.20220638
- [IY] LUO SAI ET AL: "An Antibody from Single Human V H -rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion", SCIENCE IMMUNOLOGY, 11 August 2022 (2022-08-11), US, XP055958420, ISSN: 2470-9468, Retrieved from the Internet <URL:http://dx.doi.org/10.1126/sciimmunol.add5446> DOI: 10.1126/sciimmunol.add5446
- [A] VERED KUNIK ET AL: "Structural Consensus among Antibodies Defines the Antigen Binding Site", PLOS COMPUTATIONAL BIOLOGY, vol. 8, no. 2, 23 February 2012 (2012-02-23), pages e1002388, XP055123186, DOI: 10.1371/journal.pcbi.1002388

Designated contracting state (EPC)
 AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
 BA

Designated validation state (EPC)
 KH MA MD TN

DOCDB simple family (publication)
EP 4349860 A1 20240410

DOCDB simple family (application)
EP 22382940 A 20221006